全部照片(1)

Key Documents

View All Documentation

1448956

USP

霉酚酸酯

Name: 霉酚酸酯
Brand: USP

United States Pharmacopeia (USP) Reference Standard

同義詞:

(4E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester, RS 61443, TM-MMF

登入查看組織和合約定價

全部照片(1)

About This Item

經驗公式（希爾表示法）:

C₂₃H₃₁NO₇

CAS號碼:

128794-94-5

分子量：:

433.49

MDL號碼:

MFCD00867568

分類程式碼代碼:

41116107

PubChem物質ID:

329750505

NACRES:

NA.24

推薦產品

Slide 1 of 10

1 of 10

USP

1448989

Mycophenolate sodium

Sigma-Aldrich

SML0284

霉酚酸酯

Sigma-Aldrich

S8776

氯化钠溶液

Supelco

PHR1451

霉酚酸酯

Sigma-Aldrich

C0775

结晶紫

USP

1448978

Mycophenolate Mofetil Related Compound B

USP

1465004

呋喃西林

Sigma-Aldrich

F8775

甲醛溶液

USP

1335508

布洛芬

Supelco

46364

结晶紫

等級

pharmaceutical primary standard

API 家族

mycophenolate

製造商／商標名

USP

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

15-25°C

SMILES 字串

COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN3CCOCC3

InChI

1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+

InChI 密鑰

RTGDFNSFWBGLEC-SYZQJQIISA-N

基因資訊

human ... IMPDH1(3614) , IMPDH2(3615)

尋找類似的產品？前往產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

生化／生理作用

Mycophenolate mofetil is a prodrug of mycophenolic acid (Cat. # M5255) that is cleaved by nonspecific esterases in vivo to produce the parent compound. Mycophenolic acid blocks inosine monophosphate dehydrogenase and is a potent immunosuppresive agent.

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

其他說明

Sales restrictions may apply.

訊號詞

Danger

危險聲明

H302,H360D,H372,H410

防範說明

P202 - P260 - P264 - P273 - P301 + P312 - P308 + P313

危險分類

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 1B - STOT RE 1

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析證明 (COA)

輸入產品批次/批號來搜索分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Slide 1 of 5

1 of 5

Supelco

M-106

霉酚酸标准液 CRM 溶液

Sigma-Aldrich

SML0936

特立氟胺

Supelco

50744

富马酸二甲酯

USP

1642802

他克莫司

Supelco

37094

Rapamycin

Calcineurin inhibitor sparing with mycophenolate mofetil in liver transplantion: a systematic review of randomized controlled trials.

A D Goralczyk et al.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 12(10), 2601-2607 (2012-07-21)

Liver transplant recipients are at high risk of developing acute and chronic renal failure. Moreover, introduction of the model for end-stage liver disease (MELD) score for primary allocation of liver grafts favors patients with pretransplant kidney dysfunction, which in turn

Outcomes of pancreas retransplantation after simultaneous kidney-pancreas transplantation are comparable to pancreas after kidney transplantation alone.

John Seal et al.

Transplantation, 99(3), 623-628 (2014-08-26)

There is a paucity of contemporary data describing the results of pancreas retransplantation (PRT). As a measure of utility, we wished to determine whether PRT could produce equivalent short-term and long-term recipient outcomes to primary pancreas after kidney (PAK) transplantation.

Differences in chronic intragraft inflammation between positive crossmatch and ABO-incompatible kidney transplantation.

Andrew Bentall et al.

Transplantation, 98(10), 1089-1096 (2014-06-10)

ABO-incompatible kidney transplantations (ABOiKTxs) seem to have better long-term outcomes than positive crossmatch kidney transplantations (+XMKTxs). This study aimed to assess the differences in chronic injury on histologic findings on 1- and 5-year surveillance biopsies and the clinical outcomes in

Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.

K Budde et al.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 14(12), 2796-2806 (2014-10-04)

This Phase III randomized trial examined efficacy and safety of a novel once-daily extended-release tacrolimus formulation (LCP-Tacro [LCPT]) versus twice-daily tacrolimus in de novo kidney transplantation. Primary efficacy end point was proportion of patients with treatment failure (death, graft failure

Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma.

P Satwani et al.

Leukemia, 29(2), 448-455 (2014-06-19)

The outcome of children, adolescents and young adults (CAYA) with poor-risk recurrent/refractory lymphoma is dismal (⩽30%). To overcome this poor prognosis, we designed an approach to maximize an allogeneic graft vs lymphoma effect in the setting of low disease burden.

查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務

Key Documents

霉酚酸酯

United States Pharmacopeia (USP) Reference Standard

About This Item

推薦產品

屬性

等級

API 家族

製造商／商標名

應用

格式

儲存溫度

SMILES 字串

InChI

InChI 密鑰

基因資訊

相關類別

描述

一般說明

生化／生理作用

分析報告

其他說明

相關產品

相關產品

安全資訊

象形圖

訊號詞

危險聲明

防範說明

危險分類

儲存類別代碼

水污染物質分類（WGK）

閃點（°F）

閃點（°C）

文件

分析證明 (COA)

已經擁有該產品？

客戶也查看了

同儕審查論文

技術服務